Curt Bilby

Curt Bilby is the President and CEO of Terapio and has over twenty years of executive leadership experience in the biotechnology, healthcare and information technology sectors both domestically and in Europe. Previously, Dr. Bilby was President and CEO of Seahawk Biosystems Corporation which developed a multiplexed, microarray biosensor based magnetic biochip technology developed at the Naval Research Laboratory. Prior to that, he was the Chairman and CEO of Evacyte Corporation, a company developing laser-based cancer detection and cell diagnostics using the internationally recognized Optical Cell Stretcher technology developed at The University of Texas at Austin. Dr. Bilby also served as the Président-Directeur Général of the multi-national healthcare company Eurimed, S.A. headquartered in Paris, France. Dr. Bilby has engineering degrees from Rose-Hulman Institute of Technology and Auburn University and conducted his doctoral work at The University of Texas at Austin. Of note is his selection as a Distinguished Young Alumnus of Rose-Hulman where he was also awarded an honorary doctorate.

Casey Cunningham, MD

Casey Cunningham, MD is a co-founder of Terapio where he serves as Chief Medical Officer. Dr. Cunningham received his fellowship training in oncology and hematology at Harvard Medical School, where he subsequently served on the faculty. He was also one of the founding members of the Division of Experimental Medicine at the Brigham & Women’s Hospital in Boston, where he established a basic research laboratory in Cell and Molecular Biology. Dr. Cunningham returned to Texas and to serve as the Associate Director of the Mary Crowley Cancer Research Center as well as a clinical oncologist with the US Oncology network. The Mary Crowley Cancer Research Center performs early phase drug development and clinical trials and Dr. Cunningham was the principal investigator on numerous trials, with a particular emphasis on gene and cell-based therapies. He currently serves as the Chief Scientific Officer at Santé Ventures and has also served on the Scientific Advisory Board or Clinical Advisory Board of several biotechnology and pharmaceutical companies including Genzyme, Arqule, Point Therapeutics, Evacyte plus others and has acted as a technical consultant to several venture and equity firms. Dr. Cunningham received his medical degree from the University of Texas Southwestern Medical School with a residency in Internal Medicine at the Medical College of Wisconsin. He has over 60 publications in peer-reviewed journals and many abstracts and meeting presentations.